Drug guidance
Sodium zirconium cyclosilicate for treating hyperkalaemia
Condition
Kidney
19 December 2022
Published on 19 Dec 2022
Last Updated on 19 Dec 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing sodium zirconium cyclosilicate on the MOH List of Subsidised Drugs for treating hyperkalaemia due to the uncertain extent of clinical benefit and uncertain cost effectiveness compared with current standard of care.
Sodium zirconium cyclosilicate for treating hyperkalaemia (19 December 2022) [PDF, 133 KB]
PES Sodium zirconium cyclosilicate for treating hyperkalaemia (19 December 2022) [PDF, 115 KB]